Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 21.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 21.5 Contact Hours.
This activity is supported by educational grants from AbbVie, Ariad Pharmaceuticals, Inc., Celgene Corporation, Foundation Medicine, Inc., Gilead Sciences, Inc., Incyte, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pharmacyclics, Seattle Genetics, Inc., and Takeda Oncology.
February 23-25, 2017
Trump International Miami
18001 Collins Avenue
Sunny Isles, FL 33160
Now in its 21st year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma is designed to facilitate clinician application of the wealth of emerging data in treating hematologic malignancies, choosing appropriate treatment based upon patient and tumor characteristics, and applying novel management strategies to their practices to improve the care of patients.
New for this year! We have shifted the meeting day pattern for this 3-day meeting to Thursday through mid-afternoon Saturday. This year’s program will focus on key clinical applications in leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, benign hematologic disorders, and mitigation and management of adverse events. Patient cases will be presented and discussed with the audience in a manner designed to engage their participation and in the context of methods to practically apply pivotal trial data to everyday practice. Additionally, the well-known and highly interactive Medical Crossfire® discussion panels will allow for exploration of some of the most challenging topics for which there may be many potential approaches to care.
This highly practical and interactive forum will provide a unique opportunity for oncologists and other healthcare professionals to learn from and interact with leading expert national faculty in order to increase their clinical knowledge, apply new data to practice, and ultimately improve patient outcomes.
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.
At the conclusion of this symposium, you should be better prepared to:
- Describe current and evolving genomic and molecular biomarkers that can be used to stratify risk and inform clinical decision-making in the management of hematologic malignancies
- Assess landmark clinical trial results in the context of how they impact evolving clinical practice paradigms and can be applied to personalize care and optimize outcomes
- Delineate effective strategies to proactively mitigate and manage predictable side effects related to the management of hematologic malignancies so that treatment outcomes can be maximized
- Evaluate recent clinical trial findings concerning novel compounds or strategies to manage hematologic malignancies
- Consider the therapeutic implications of emerging data on evolving treatment paradigms for patients with hematologic tumors
Andre Goy, MD, MS
Chairman and Director, Chief of Lymphoma
Director, Clinical and Translational Cancer Research
John Theurer Cancer Center
Hackensack Meridian Health
Professor of Medicine, Georgetown University
Sagar Lonial, MD, FACP
Professor, Emory School of Medicine
Chair, Department of Hematology & Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University